Febuxostat National Contract

Contract SPE2D2-22-D-0142 is a national pharmaceutical procurement award issued by the Defense Logistics Agency (DLA) Troop Support to Golden State Medical Supply, Inc. for the supply of Febuxostat 40 MG and 80 MG tablets. Originally awarded on April 7, 2022, with an initial value of $73,378,778.32, the contract covers a base year and four option years. Through modification P00001, the total contract value was decreased by $26,029,681.48, resulting in a revised total of $47,349,096.84. The products are manufactured by Hikma Pharmaceuticals USA, Inc. in Columbus, Ohio, and distributed via FOB Destination terms. The contract includes several critical modifications to pricing and compliance. Option Year 1 was exercised in April 2023, and Option Year 2 was exercised in April 2024, with the latter implementing a price reduction for 30-count bottles from $134.89 to $129.98. A significant update via modification P00004 integrated Drug Supply Chain Security Act (DSCSA) language and strict bar code labeling standards, requiring GSI-128 or HIBCC standards with ANSI/ISO/IEC grade C quality to ensure traceability. The agreement also clarifies that the Department of Veterans Affairs is not obligated to use the contract through the Pharmaceutical Prime Vendor Program. Administratively, the contract is set aside for various small business categories, including HubZone and Service-Disabled Veteran-Owned Small Businesses. It incorporates extensive FAR and DFARS clauses governing cybersecurity, such as the safeguarding of covered defense information, and environmental reporting for greenhouse gas emissions. Invoicing is handled electronically through the DLA or VA Pharmaceutical Prime Vendor systems, with performance monitored through initial bar code verification and routine audits.